

# the **ADBL** report

Issue #123, November 2021

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross  
The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

## EXPERT COMMITTEE MEMBERS:

Fiona Clement, PhD, (Acting Chair)  
Caitlin A. Clarke, BScPhm, PharmD  
Margaret Gray, BSP, FCSHP  
Michael Kolber, BSc, MD, CCFP, MSc  
Naeem Ladhani, BScPharm  
Tony Nickonchuk, BScPharm  
Glen J. Pearson, BScPhm, PharmD, FCSHP, FCCS  
Donna Woloschuk, BSP, PharmD, M.Ed. FCSHP

## ALBERTA HEALTH LIAISON:

Andrea Nagle, BScPharm, LLB

## ADMINISTRATIVE AND SCIENTIFIC SUPPORT:

Julia Chan, BSc (Pharm)  
Amanda Chung, BSc (Pharm)  
Sherry Dieleman, BSc (Pharm), MSc  
Connie Lussier, BSP, MA

## In this issue:

- **Brief Summary of Drug Review Activities**
- **Highlights of:**
  - ❖ **Products Originally Reviewed via the CDR**
  - ❖ **Interchangeable Drug Products Added**
  - ❖ **Biosimilar Drug Products Added**
  - ❖ **Drug Products Added**
  - ❖ **Changes to Currently Listed Products**

## **Brief Summary of Drug Review Activities**

The Expert Committee on Drug Evaluation and Therapeutics met on September 21, 2021. The Committee reviewed Manufacturer submissions for twenty-eight (28) Drug Products for potential listing, or change in listing, on the *ADBL*. The Committee also considered information for a number of supplementary assessments of the coverage status of eight (8) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, thirty-eight (38) Drug Products underwent Expedited Review for listing on the *ADBL* effective October 1, 2021, and twenty-six (26) Drug Products underwent Expedited Review for listing on the *ADBL* effective November 1, 2021.

The following are highlights of recent changes to the *ADBL* and other topics of general interest. A complete list of changes, as well as the full *ADBL* may be accessed at <https://www.ab.bluecross.ca/dbl/publications.php>

## **Highlights of Products Originally Reviewed via the Common Drug Review (CDR)**

The following Drug Products were reviewed by CDR and added to the *ADBL* effective September 24, 2021:

- **TRIKAFTA\* 100 mg/50 mg/75 mg & 150 mg oral tablets** (elexacaftor/tezacaftor/ivacaftor) (ivacaftor) (VER) via Special Authorization (SA)

The following Drug Products were reviewed by CDR and the Expert Committee and added to the *ADBL* effective November 1, 2021:

- **ATECTURA BREEZHALER\* 150 mcg/80 mcg, 150 mcg/160 mcg & 150 mcg/320 mcg inhalation capsules** (indacaterol acetate/mometasone furoate) (VLP) via Step Therapy/SA
- **ENERZAIR BREEZHALER\* 150 mcg/50 mcg/160 mcg inhalation capsule** (indacaterol acetate/glycopyrronium bromide/mometasone furoate) (VLP) via SA
- **NEXPLANON 68 mg subdermal implant** (etonogestrel) (ORC)

A complete list of changes, as well as the full *ADBL* may be accessed at <https://www.ab.bluecross.ca/dbl/publications.php>.

\*Please refer to the current *ADBL* for explanations of coverage, including a listing of coverage criteria (where applicable).\*

ABC81171 (11/2021)

## ***Highlights of Interchangeable (IC) Drug Products Added***

Addition of the following Entry IC Drug Product to the *ADBL* has resulted in the creation of a New IC Grouping, effective November 1, 2021:

- **ACCEL-HYOSCINE 10 mg tablet** (hyoscine butylbromide) (ACP)

## ***Highlights of Biosimilar Drug Products Added***

The following Biosimilar Drug Products were added to the *ADBL* effective October 1, 2021:

- **TRURAPI 100 unit/mL injection cartridge & TRURAPI SOLOSTAR 100 unit/mL pen injection** (insulin aspart) (SAV)

## ***Highlights of Drug Products Added***

The following Drug Product was added to the *ADBL* effective October 1, 2021:

- **ODAN-METHADONE (CHERRY FLAVOUR) 10 mg/mL oral solution** (methadone hydrochloride) (ODN)

The following Drug Products were reviewed by the Expert Committee and added to the *ADBL* effective November 1, 2021:

- **LOSEC MUPS 20 mg delayed-release tablet** (omeprazole) (CAG)
- **SOMATULINE AUTOGEL\* 60 mg/0.5 mL, 90 mg/0.5 mL & 120 mg/0.5 mL injection syringes** (lanreotide acetate) (ISP) via SA for control of symptoms in patients with metastatic carcinoid tumors

## ***Highlights of Changes to Currently Listed Products***

The benefit listing status of the following Drug Products have been changed from Regular Benefits to Restricted Benefits effective October 1, 2021:

- **NOVORAPID 100 unit/mL injection vial and cartridge & NOVORAPID FLEXTOUCH 100 unit/mL pen injection** (insulin aspart) (NNA)

A complete list of changes, as well as the full *ADBL* may be accessed at <https://www.ab.bluecross.ca/dbl/publications.html>.

\*Please refer to the current *ADBL* for explanations of coverage, including a listing of coverage criteria (where applicable).\*

ABC81171 (11/2021)